Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Sponsor: Janssen Research & Development, LLC
Summary
The goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help patients achieve a response and for how long?
Official title: A Phase 1b Multicenter, Open-Label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2023-11-06
Completion Date
2040-01-03
Last Updated
2026-03-13
Healthy Volunteers
No
Interventions
JNJ-90009530
JNJ-90009530, an autologous Chimeric Antigen Receptor (CAR) - T therapy targeting CD20
Locations (15)
University of Iowa Hospital
Iowa City, Iowa, United States
University of Kentucky
Lexington, Kentucky, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Rutgers University
New Brunswick, New Jersey, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center
Houston, Texas, United States
Royal Prince Alfred Hospital
Camperdown, Australia
Monash Medical Centre
Clayton, Australia
Austin Hospital
Heidelberg, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Westmead Hospital
Westmead, Australia
Hadassah Medical Center
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
University College London Hospitals
London, United Kingdom